Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | MITF | O75030 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16324474 | 0.81 | ALDH1A1 (0.68) | ALDH1A1PKMMITFKMT2ASOS1 | |
| SCHEMBL28290761 | 0.76 | MITF (0.62) | ALDH1A1PKMMITFKMT2ASOS1 | |
| SCHEMBL1520534 | 0.76 | PKM (0.64) | ALDH1A1PKMMITFKMT2ASOS1 | |
| SCHEMBL3504600 | 0.75 | ALDH1A1 (0.68) | ALDH1A1PKMMITFKMT2ASOS1 | |
| SCHEMBL9873776 | 0.75 | L3MBTL1 (0.49) | ALDH1A1PKMMITFKMT2APOLB | |
| SCHEMBL4058834 | 0.75 | ALDH1A1 (0.62) | ALDH1A1PKMMITFKMT2ASOS1 | |
| SCHEMBL25252035 | 0.74 | ALDH1A1 (0.57) | ALDH1A1PKMMITFKMT2ASOS1 | |
| SCHEMBL28290789 | 0.74 | ALDH1A1 (0.57) | ALDH1A1PKMMITFKMT2ASOS1 | |
| SCHEMBL29170726 | 0.74 | ALDH1A1 (0.66) | ALDH1A1PKMMITFKMT2ASOS1 | |
| SCHEMBL13431485 | 0.73 | ALDH1A1 (0.75) | ALDH1A1PKMMITFKMT2ASOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-1213268-A | — | — | None | — | — | JP | disclosed |
| US-20220047555-A1 | ANTIMICROBIAL DRUG SYNTHESIS AND THERAPEUTIC COMPOSITIONS | GREGG JOHN MALCOLM HALL (US) | 2022-02-17 | — | — | US | disclosed |
| CN-100376559-C | Method for preparing secnidazole | ZHEJIANG SUBOER PHARMACEUTICAL (CN) | 2008-03-26 | — | — | CN | disclosed |
| CN-1850806-A | Method for preparing secnidazole | ZHEJIANG SUBOER PHARMACEUTICAL (CN) | 2006-10-25 | — | — | CN | disclosed |
| CN-1279025-C | Improved method of preparing secnidazole | GEN CHEMICAL LAB LTD (IN) | 2006-10-11 | — | — | CN | disclosed |
| CN-1442410-A | Improved method of preparing secnidazole | GEN CHEMICAL LAB LTD (IN) | 2003-09-17 | — | — | CN | disclosed |
| CN-1055536-A | The preparation method of 1-hydroxyalkyl-5-nitroimidazole | RHONE POULENC RORER SA (FR) | 1991-10-23 | — | — | CN | disclosed |
| US-5023361-A | Process for preparing hydroxyalkylating agents, the agents so obtained, and their use | RHONE-POULENC SANTE (FR) | 1991-06-11 | — | — | US | disclosed |
| US-4925950-A | Process for preparing 1-hydroxyalkyl-5-nitroimidazole | RHONE-POULENC SANTE (FR) | 1990-05-15 | — | — | US | disclosed |
| US-4925949-A | Process for preparing 1-alkyl-5-nitroimidazoles | RHONE-POULENC SANTE (FR) | 1990-05-15 | — | — | US | disclosed |
| US-4925951-A | Process for preparing 1-hydroxyalkyl-2-methyl-5-nitroimidazoles | RHONE-POULENC SANTE (FR) | 1990-05-15 | — | — | US | disclosed |
| US-4925952-A | Process for preparing 1-hydroxyalkyl-5-nitroimidazoles | RHONE-POULENC SANTE (FR) | 1990-05-15 | — | — | US | disclosed |
| JP-H01213268-A | PREPARATION OF 1-ALKYL-5-NITROIMIDAZOLE | RHONE POULENC SANTE | 1989-08-28 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220047555-A1 | ANTIMICROBIAL DRUG SYNTHESIS AND THERAPEUTIC COMPOSITIONS | OAT, RIOX2, OTC | ALDH1A1 659/4885PKM 1938/4885MITF 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.